JP2021527689A5 - - Google Patents
Info
- Publication number
- JP2021527689A5 JP2021527689A5 JP2020570911A JP2020570911A JP2021527689A5 JP 2021527689 A5 JP2021527689 A5 JP 2021527689A5 JP 2020570911 A JP2020570911 A JP 2020570911A JP 2020570911 A JP2020570911 A JP 2020570911A JP 2021527689 A5 JP2021527689 A5 JP 2021527689A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- cells
- vector
- interleukin
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688810P | 2018-06-22 | 2018-06-22 | |
| US62/688,810 | 2018-06-22 | ||
| PCT/US2019/038547 WO2019246563A1 (en) | 2018-06-22 | 2019-06-21 | Chimeric transmembrane proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527689A JP2021527689A (ja) | 2021-10-14 |
| JP2021527689A5 true JP2021527689A5 (enExample) | 2022-06-21 |
Family
ID=67352580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570911A Pending JP2021527689A (ja) | 2018-06-22 | 2019-06-21 | キメラ膜貫通タンパク質及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11708401B2 (enExample) |
| EP (1) | EP3810645A1 (enExample) |
| JP (1) | JP2021527689A (enExample) |
| KR (1) | KR20210025525A (enExample) |
| CN (1) | CN112368298A (enExample) |
| AU (2) | AU2019288733C1 (enExample) |
| BR (1) | BR112020025804A2 (enExample) |
| CA (1) | CA3102641A1 (enExample) |
| IL (1) | IL279505A (enExample) |
| MX (1) | MX2020013977A (enExample) |
| SG (1) | SG11202011751WA (enExample) |
| TW (1) | TWI809130B (enExample) |
| WO (1) | WO2019246563A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230167769A (ko) * | 2016-08-26 | 2023-12-11 | 베이롤 칼리지 오브 메드신 | 세포 치료요법을 위한 항상성 활성 사이토킨 수용체 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| EP4714966A2 (en) | 2017-09-26 | 2026-03-25 | Cero Therapeutics Holdings, Inc. | Chimeric engulfment receptor molecules and methods of use |
| CN111819192A (zh) | 2018-03-02 | 2020-10-23 | 艾洛基治疗公司 | 可诱导的嵌合细胞激素受体 |
| EP3774906A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| MX2020010241A (es) | 2018-03-28 | 2020-10-16 | Cero Therapeutics Inc | Composiciones de inmunoterapia celular y usos de las mismas. |
| US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
| AU2020232216B2 (en) | 2019-03-01 | 2025-09-25 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
| PE20211902A1 (es) | 2019-03-01 | 2021-09-27 | Allogene Therapeutics Inc | Receptores de citocinas quimericos constitutivamente activos |
| CN114391021B (zh) | 2019-06-21 | 2026-01-16 | 凯德药业股份有限公司 | TGF-β受体和使用方法 |
| GB201911187D0 (en) | 2019-08-05 | 2019-09-18 | Autolus Ltd | Receptor |
| US12528856B2 (en) | 2019-08-30 | 2026-01-20 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising TGF β binding domains |
| US20210253696A1 (en) * | 2020-01-21 | 2021-08-19 | Cero Therapeutics, Inc. | Bivalent chimeric engulfment receptors and uses thereof |
| MX2022010340A (es) | 2020-02-24 | 2022-09-19 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas. |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| EP4305053A1 (en) * | 2021-03-11 | 2024-01-17 | Kite Pharma, Inc. | Improving immune cell function |
| WO2022261061A1 (en) | 2021-06-08 | 2022-12-15 | Kite Pharma, Inc. | Gpc3 binding molecules |
| KR20240022575A (ko) * | 2021-06-16 | 2024-02-20 | 센티 바이오사이언시스, 인코포레이티드 | 아머링된 키메라 수용체 및 이의 사용 방법 |
| JPWO2023276395A1 (enExample) * | 2021-06-28 | 2023-01-05 | ||
| CN113736810B (zh) * | 2021-09-08 | 2024-05-24 | 苏州因特药物研发有限公司 | 构建体、载体、蛋白、细胞、制备方法、产品及应用 |
| WO2023197980A1 (zh) * | 2022-04-11 | 2023-10-19 | 苏州沙砾生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| CN117683139A (zh) * | 2022-09-09 | 2024-03-12 | 信达细胞制药(苏州)有限公司 | 组成型嵌合细胞因子受体及表达其的免疫细胞及应用 |
| CN117402262A (zh) * | 2022-10-19 | 2024-01-16 | 上海君赛生物科技有限公司 | 基于lag3的嵌合免疫细胞辅助受体及其用途 |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| CN117402231B (zh) * | 2023-12-14 | 2024-04-09 | 南方医科大学南方医院 | 一种自发传递il-21信号的受体及其应用 |
| WO2026008700A1 (en) * | 2024-07-03 | 2026-01-08 | Immunofusion Bv | Il7r alpha signalling domain, chimeric antigen receptor and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| AU671606B2 (en) | 1991-10-31 | 1996-09-05 | Whitehead Institute For Biomedical Research | TGF-beta type receptor cDNAs and uses therefor |
| DE69332026T2 (de) | 1992-10-29 | 2002-10-31 | Celtrix Pharmaceuticals, Inc. | Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| US20030125251A1 (en) | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
| KR100953520B1 (ko) | 2001-06-22 | 2010-04-21 | 츄가이 세이야꾸 가부시키가이샤 | 항글리피칸 3항체를 포함하는 항암제 |
| WO2004022597A1 (ja) | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体 |
| WO2006012414A2 (en) | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Novel polyadenylation signal for use in expression vectors |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| JP2011526792A (ja) * | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質 |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US8507222B2 (en) | 2010-09-21 | 2013-08-13 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
| EP2699603B1 (en) | 2011-04-19 | 2016-03-02 | The United States of America As Represented by the Secretary Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| PL3489254T3 (pl) | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| SG11201407972RA (en) | 2012-06-01 | 2015-01-29 | Us Health | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| US20150359853A1 (en) | 2012-10-24 | 2015-12-17 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| DK2956175T3 (da) | 2013-02-15 | 2017-11-27 | Univ California | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf |
| CN113684185A (zh) | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| CN104140974B (zh) | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| CN106795221B (zh) | 2014-04-03 | 2022-06-07 | 塞勒克提斯公司 | 用于癌症免疫治疗的cd33特异性嵌合抗原受体 |
| US9926377B2 (en) | 2014-05-22 | 2018-03-27 | Genentech, Inc. | Anti-GPC3 antibodies and immunoconjugates |
| US10093746B2 (en) | 2014-09-04 | 2018-10-09 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
| JP2017529851A (ja) | 2014-09-26 | 2017-10-12 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| EP3245288A1 (en) | 2015-01-12 | 2017-11-22 | Pieris Pharmaceuticals GmbH | Engineered t cells and uses therefor |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| CN121102467A (zh) | 2016-04-22 | 2025-12-12 | 克莱格医学有限公司 | 用于细胞免疫疗法的组合物和方法 |
| CN105949324B (zh) | 2016-06-30 | 2019-08-27 | 上海恒润达生生物科技有限公司 | 靶向gpc3的嵌合抗原受体及其用途 |
| KR20230167769A (ko) * | 2016-08-26 | 2023-12-11 | 베이롤 칼리지 오브 메드신 | 세포 치료요법을 위한 항상성 활성 사이토킨 수용체 |
| CN109863242A (zh) | 2016-08-30 | 2019-06-07 | 纪念斯隆-凯特林癌症中心 | 用于治疗病毒感染和其它感染的免疫细胞组合物和使用方法 |
| US11408005B2 (en) | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| MX2019008221A (es) | 2017-01-10 | 2019-12-09 | Univ Yamaguchi | Anticuerpo anti-gpc3. |
| EP3615574A4 (en) | 2017-04-26 | 2021-02-24 | Eureka Therapeutics, Inc. | SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE |
| ES2948647T3 (es) | 2017-05-04 | 2023-09-15 | Acceleron Pharma Inc | Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas |
| CN111683962B (zh) | 2017-11-10 | 2025-05-16 | 美国政府(由卫生和人类服务部的部长所代表) | 靶向肿瘤抗原的嵌合抗原受体 |
| CN118420783A (zh) | 2017-12-06 | 2024-08-02 | 恺兴生命科技(上海)有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
-
2019
- 2019-06-21 CA CA3102641A patent/CA3102641A1/en active Pending
- 2019-06-21 MX MX2020013977A patent/MX2020013977A/es unknown
- 2019-06-21 JP JP2020570911A patent/JP2021527689A/ja active Pending
- 2019-06-21 AU AU2019288733A patent/AU2019288733C1/en active Active
- 2019-06-21 KR KR1020207036743A patent/KR20210025525A/ko not_active Ceased
- 2019-06-21 TW TW108121854A patent/TWI809130B/zh active
- 2019-06-21 EP EP19742108.4A patent/EP3810645A1/en active Pending
- 2019-06-21 BR BR112020025804-0A patent/BR112020025804A2/pt not_active IP Right Cessation
- 2019-06-21 US US16/449,089 patent/US11708401B2/en active Active
- 2019-06-21 WO PCT/US2019/038547 patent/WO2019246563A1/en not_active Ceased
- 2019-06-21 CN CN201980042055.XA patent/CN112368298A/zh active Pending
- 2019-06-21 SG SG11202011751WA patent/SG11202011751WA/en unknown
-
2020
- 2020-12-16 IL IL279505A patent/IL279505A/en unknown
-
2023
- 2023-02-28 AU AU2023201197A patent/AU2023201197A1/en not_active Abandoned
- 2023-06-01 US US18/327,651 patent/US20230416339A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527689A5 (enExample) | ||
| US20240059754A1 (en) | Chimeric antigen receptors and enhancement of anti-tumor activity | |
| Ajina et al. | Strategies to address chimeric antigen receptor tonic signaling | |
| CN111836827B (zh) | 包含nkg2d结构域的多特异性嵌合受体和其使用方法 | |
| ES2909973T3 (es) | Receptores quiméricos para el antígeno que se dirigen a HER2 | |
| JP6961497B2 (ja) | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 | |
| EP3227339B1 (en) | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof | |
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| CA3091681A1 (en) | Inducible chimeric cytokine receptors | |
| JP2018529376A5 (enExample) | ||
| JP2024069352A5 (enExample) | ||
| JP2020506700A5 (enExample) | ||
| JP2021536265A5 (enExample) | ||
| CN113621073A (zh) | 一种新型嵌合受体组合物、重组载体、细胞及其应用 | |
| JP2024534471A5 (enExample) | ||
| JP2024528988A5 (enExample) | ||
| WO2020259541A1 (zh) | 一种用于肿瘤治疗的嵌合抗原受体t淋巴细胞及其制备方法与应用 | |
| IL309653A (en) | Composition and methods for selective degradation of transgenic proteins | |
| US20250345429A1 (en) | Compositions and methods comprising chimeric adaptor polypeptides | |
| EP3724339A2 (en) | Pooling signaling and costimulatory domains in flexible car design | |
| KR20230084470A (ko) | 면역 세포 기능의 향상 | |
| KR20230155521A (ko) | 면역 세포 기능의 향상 | |
| CN113402621A (zh) | 含有嵌合抗原受体的融合蛋白及其应用 | |
| CN112300288B (zh) | 一种cik细胞的嵌合抗原受体car及其应用 | |
| JP2025506515A5 (enExample) |